Brian Hess, M.D.

I am interested in designing clinical trials that study the impact of novel therapeutics in Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). I currently serve as the clinical director of the adult CAR T-cell program as well as the disease focus group leader of hematologic malignancies, oversee the lymphoma clinical trial portfolio, and have served as a member of the data safety and monitoring committee at MUSC since 2018. I have developed the phase I study oral azacitadine (CC-486) plus R-ICE salvage chemotherapy in (R/R) DLBCL, investigating the role of epigenetic priming in inducing chemotherapy sensitivity in R/R DLBCL. I have also collaborated with colleagues at MUSC-HCC to develop and carry out a phase 1B dose escalation study of metabolically fit CD19 chimeric antigen receptor (CAR) T-cells with CD34 selection markers in adult patients with relapsed or refractory CD19 B-cell NHL and CLL/SLL.